QIAcuity instruments – Features and specifications
| QIAcuity One | QIAcuity Four | QIAcuity Eight | |
|---|---|---|---|
| Plates processed | 1 | 4 | 8 |
| Detection channels (multiplexing) | 2 or 5 | 5 | 5 |
| Thermocycler(s) | 1 | 1 | 2 |
| Time to result | Under 2h | First plate under 2 h Every ~60 min a following plate |
First plate under 2 h Every ~30 min a following plate |
| Throughput (samples processed in a work day) | Up to 384 (96-well) Up to 96 (24-well) |
Up to 672 (96-well) Up to 168 (24-well) |
Up to 1248 (96-well) Up to 312 (24-well) |
Unveiling the magic inside
Reimagining familiarity, ease of use and finer resolution, we have developed these nanoplates with superior partitioning, meaning unparalleled precision and sensitivity gain for your assays.
Nanoplates – Features and specifications
| Specifications | Applications | |
|---|---|---|
| Nanoplate 26K 24-well | 24-well × approx. 26,000 partitions |
Rare mutation detection, liquid biopsy, pathogen detection, etc. |
| Nanoplate 8.5K 24-well | 24-well × approx. 8,500 partitions |
CNV determination, NGS library quantification, genome edit detection, etc. |
| Nanoplate 8.5K 96-well | 96-well × approx. 8,500 partitions |
CNV determination, NGS library quantification, genome edit detection, etc. |
Kits and reagents – Features and specifications
| Specifications | Applications | |
|---|---|---|
| QIAcuity Probe PCR Kit | For single and multiplex use (1- to 5-plex) | Optimized for best performance in nanoplate microfluidic Includes special reference dye needed for dPCR analysis and counting analyzable partitions |
| QIAcuity EG PCR Kit | EG-based master mix | Optimized for best performance in nanoplate microfluidic Includes special reference dye needed for dPCR analysis and counting analyzable partitions |
*For RNA samples and cDNA synthesis, the QuantiTect Reverse Transcription Kit is recommended.
Product Groups – Discover featured QIAcuity products
Publications
Browse a growing list of articles featuring QIAcuity dPCR products.Boogaerts T et al. (2021). An alternative approach for bioanalytical assay optimization for wastewater-based epidemiology of SARS-CoV-2. Science of The Total Environment,Volume 789, Article 148043.
Luo Y et al. (2020). Massively parallel single-molecule telomere length measurement with digital real-time PCR. Sci Adv. 6(34):eabb7944.
Lee EG et al. (2021). TOMM40 RNA Transcription in Alzheimer’s Disease Brain and Its Implication in Mitochondrial Dysfunction. Genes. 12, 871.
Wirtz RM et al. (2021). FGFR testing from matched tissue and urine samples within the prospective real world clinico-pathological register trial BRIDGister. Journal of Clinical Oncology. 39:15_suppl, e16532-e16532.
[Preprint version only] Yang JX et al. (2021). Digital PCR quantification of DNA, RNA and extracellular microRNA of mouse oocytes.
[Preprint version only] Ferasin L et al. (2021). Myocarditis in naturally infected pets with the British variant of COVID-19.
[Preprint version only] Wu X et al. (2021). A Warm-start Digital CRISPR-based Method for the Quantitative Detection of Nucleic Acids.
How to choose a QIAcuity Digital PCR System
Together with its nanoplates, kits and assays, each instrument delivers high performance and data quality, with flexible throughput and multiplexing. Ask the right questions to evaluate your needs.
- What applications will you perform most frequently?
- Which instrumentation options best enable your scale of study?
- What are the costs for product care beyond the initial investment?
For further guidance about comprehensive product care when making your decision, download the QIAcuity Service Brochure.
Can your research benefit from having QIAcuity?
Make the right choice for your laboratory.
*The GT-Digital SARS-CoV-2 Wastewater Surveillance Assay For QIAcuity is currently available in the United States and Canada. Contact your country representative for product availability details. GT Molecular is The Molecular App Company™.
The QIAcuity is intended for molecular biology applications. This product is not intended for the diagnosis, prevention or treatment of a disease. Therefore, the performance characteristics of the product for clinical use (i.e., diagnostic, prognostic, therapeutic or blood banking) is unknown.